Efficacy of alendronate in the treatment of low bone density in the pediatric and young adult population

Journal of Bone and Joint Surgery

Volumn 94, Issue 10, 2012, Pages e62(1)-

  Dominguez Bartmess, Samuel Norman ^c   Tandberg, Dan ^a   Cheema, Asad M ^a   Szalay, Elizabeth A ^b  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NEW MEXICO   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID;

ADOLESCENT; ARTICLE; BONE DENSITY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR; HUMAN; LUMBAR SPINE; MALE; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

EID: 84863650658     PISSN: 00219355     EISSN: 15351386     Source Type: Journal    
DOI: 10.2106/JBJS.K.00751     Document Type: Article

References (23)

1. Khan AA, Bachrach L, Brown JP, Hanley DA, Josse RG, Kendler DL, Leib ES, Lentle BC, Leslie WD, Lewiecki EM, Miller PD, Nicholson RL, O'Brien C, Olszynski WP, Theriault MY, Watts NB; Canadian Panel of the International Society of Clinical Densitometry. Standards and guidelines for performing central dual-energy x-ray absorptiometry in premenopausal women, men, and children. J Clin Densitom. 2004;7:51-64.
2. Henderson RC, Kairalla J, Abbas A, Stevenson RD. Predicting low bone density in children and young adults with quadriplegic cerebral palsy. Dev Med Child Neurol. 2004;46:416-9. (Pubitemid 38696982)
3. Henderson RC, Lin PP, Greene WB. Bone-mineral density in children and adolescents who have spastic cerebral palsy. J Bone Joint Surg Am. 1995;77:1671-81.
4. Sturm PF, Alman BA, Christie BL. Femur fractures in institutionalized patients after hip spica immobilization. J Pediatr Orthop. 1993;13:246-8. (Pubitemid 23091087)
5. Forteo (teriparatide [rDNA origin] injection). http://www.accessdata.fda. gov/ drugsatfda-docs/label/2008/021318s015lbl.pdf. Accessed 2012 Jan 4.
6. Liberman UA, Weiss SR, Bröll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW Jr, Dequeker J, Favus M. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med. 1995; 333:1437-43.
7. Ward L, Tricco AC, Phuong P, Cranney A, Barrowman N, Gaboury I, Rauch F, Tugwell P, Moher D. Bisphosphonate therapy for children and adolescents with secondary osteoporosis. Cochrane Database Syst Rev. 2007;4:CD005324.
8. Henderson RC, Lark RK, Kecskemethy HH, Miller F, Harcke HT, Bachrach SJ. Bisphosphonates to treat osteopenia in children with quadriplegic cerebral palsy: a randomized, placebo-controlled clinical trial. J Pediatr. 2002;141:644-51. (Pubitemid 35292762)
9. Castillo H, Samson-Fang L; American Academy for Cerebral Palsy and Developmental Medicine Treatment Outcomes Committee Review Panel. Effects of bisphosphonates in children with osteogenesis imperfecta: an AACPDM systematic review. Dev Med Child Neurol. 2009;51:17-29.
10. DiMeglio LA, Peacock M. Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta. J Bone Miner Res. 2006;21:132-40. (Pubitemid 43023235)
11. Li Z, Chines AA,Meredith MP. Statistical validation of surrogate endpoints: is bone density a valid surrogate for fracture? JMusculoskelet Neuronal Interact. 2004;4:64-74. (Pubitemid 38714796)
12. Sandrick K. DXA remains gold standard for assessing spine and femoral head. Diagn Imaging (San Franc). 1998;Suppl Bone Mass:8-11.
13. Hamdy RC, Petak SM, Lenchik L; International Society for Clinical Densitometry Position Development Panel and Scientific Advisory Committee. Which central dual X-ray absorptiometry skeletal sites and regions of interest should be used to determine the diagnosis of osteoporosis? J Clin Densitom. 2002;5 Suppl:S11-8.
14. Henderson RC, Lark RK, Newman JE, Kecskemthy H, Fung EB, Renner JB, Harcke HT. Pediatric reference data for dual X-ray absorptiometric measures of normal bone density in the distal femur. AJR Am J Roentgenol. 2002;178: 439-43. (Pubitemid 34098057)
15. Szalay EA, Harriman D. Adapting pediatric DXA scanning to clinical orthopaedics. J Pediatr Orthop. 2006;26:686-90. (Pubitemid 44315853)
16. Harcke HT, Taylor A, Bachrach S, Miller F, Henderson RC. Lateral femoral scan: an alternative method for assessing bone mineral density in children with cerebral palsy. Pediatr Radiol. 1998;28:241-6. (Pubitemid 28177334)
17. Faulkner RA, Bailey DA, Drinkwater DT, McKay HA, Arnold C, Wilkinson AA. Bone densitometry in Canadian children 8-17 years of Age. Calcif Tissue Int. 1996; 59:344-51. (Pubitemid 26367081)
18. Southard RN, Morris JD, Mahan JD, Hayes JR, Torch MA, Sommer A, Zipf WB. Bone mass in healthy children: measurement with quantitative DXA. Radiology. 1991;179:735-8.
19. Al Muderis M, Azzopardi T, Cundy P. Zebra lines of pamidronate therapy in children. J Bone Joint Surg Am. 2007;89:1511-6. (Pubitemid 47041528)
20. Fosamax (alendronate sodium) tablets and oral solution. http://www. accessdata.fda.gov/drugsatfda-docs/label/2010/020560s051s055s057, 021575s012s016s018lbl.pdf. Accessed 2012 Jan 4.
21. Sholas MG, Tann B, Gaebler-Spira D. Oral bisphosphonates to treat disuse osteopenia in children with disabilities: a case series. J Pediatr Orthop. 2005;25: 326-31. (Pubitemid 40594070)
22. Hawker GA, Ridout R, Harris VA, Chase CC, Fielding LJ, Biggar WD. Alendronate in the treatment of low bone mass in steroid-treated boys with Duchennes muscular dystrophy. Arch Phys Med Rehabil. 2005;86:284-8. (Pubitemid 40215291)
23. Bianchi ML, Cimaz R, Bardare M, Zulian F, Lepore L, Boncompagni A, Galbiati E, Corona F, Luisetto G, Giuntini D, Picco P, Brandi ML, Falcini F. Efficacy and safety of alendronate for the treatment of osteoporosis in diffuse connective tissue diseases in children: a prospective multicenter study. Arthritis Rheum. 2000;43:1960-6.